Summary

Treatment with dapagliflozin (DAPA) is not associated with an increased risk of acute renal toxicity or long-term deterioration of renal function in patients with type 2 diabetes mellitus (T2DM) according to the results of a pooled analysis of 12 studies [NCT00263276; NCT00972244; NCT00528372; NCT00736879; NCT00528879; NCT00855166; NCT00357370; NCT00680745; NCT00683878; NCT00673231; NCT00643851; NCT00859898].